The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis
Abstract
The occurrence of large cell transformation has been well documented in a subgroup of patients with mycosis fungoides/Sezary syndrome (MF/SS). However, because of the rarity of MF/SS, little is known about the influence of clinicopathologic features in predicting large cell transformation and about outcome in the transformed cases. We evaluated all patients with MF/SS who were registered in our clinic during the study period and for whom pathologic slides for review were available or could be obtained. Disease was classified as transformed if biopsy showed large cells (≥4 times the size of a small lymphocyte) in more than 25% of the infiltrate or if they formed microscopic nodules. Twenty-six patients with transformation were identified from a total of 115 evaluable cases with a diagnosis of MF/SS. The actuarial cumulative probability of transformation reached 39% in 12 years. The median time from diagnosis of MF/SS to transformation was 12 months (range, 0 to 128 months). Thirty-one percent of all patients with stage IIB-IV disease at presentation eventually transformed versus 14% of those with stage I-IIA (P= .03), with transformation being especially common in patients with tumors (T3), 46% of whom transformed. Combining elevated β2 microglobulin and lactic dehydrogenase (neither elevated v one or both elevated) was also predictive for transformation (P = .009). The median survival from initial diagnosis of MF/SS for the transformed patients was 37 months versus 163 months for the untransformed group (P = .0029). The median survival from transformation was 19.4 months (range, 2+ to 138 months). The following characteristics were associated with an inferior survival in transformed patients: (1) early transformation (<2 years from the diagnosis v ≥2 years; P = .011) and (2) advanced stage (IIB-IV v I-IIA; 2-year survival, 23% v 86%;P = .0035). We conclude that MF/SS patients with stages IIB-IV disease and, in particular, those with tumors have a high incidence of large-cell transformation. Patients with transformation have a relatively poor survival, especially if transformation occurs early (within 2 years) in the course of disease or if they are staged as IIB or higher. © 1998 by The American Society of Hematology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Hsu, S. M., Raine, L., & Fanger, H. (1981) · Journal of Histochemistry & Cytochemistry · doi:10.1177/29.4.6166661 · Cited by 14,140
A generalized Wilcoxon test for comparing arbitrarily singly-censored samples
Gehan, E. A. (1965) · Biometrika · doi:10.1093/biomet/52.1-2.203 · Cited by 3,406
Willemze, R., Kerl, H., Sterry, W., Berti, E., Cerroni, L., Chimenti, M. S., Díaz-Pérez, J. L., Geerts, M., Goos, M., Knobler, R., et al. (1997) · PubMed · doi:10.1182/blood.v90.1.354 · Cited by 1,270
Immunologic characterization of human malignant lymphomas
Lukes, R. J., & Collins, R. D. (1974) · Cancer · doi:10.1002/1097-0142(197410)34:8+<1488::aid-cncr2820340822>3.0.co;2-c · Cited by 1,092
Cutaneous T-Cell Lymphomas: The Sézary Syndrome, Mycosis Fungoides, and Related Disorders
LUTZNER, M., EDELSON, R., SCHEIN, P., GREEN, I., KIRKPATRICK, C., & AHMED, A. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-83-4-534 · Cited by 635
Kaye, F. J., Bunn, P. A., Steinberg, S. M., Stocker, J. L., Ihde, D. C., Fischmann, A. B., Glatstein, E. J., Schechter, G. P., Phelps, R. M., Foss, F. M., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212603 · Cited by 487
Mycosis fungoides and Sezary syndrome [see comments]
Diamandidou, E., Cohen, P., & Kurzrock, R. (1996) · Blood · doi:10.1182/blood.v88.7.2385.bloodjournal8872385 · Cited by 273
Self-citationCombined modality therapy for cutaneous T-cell lymphoma
Duvic, M. A., Lemak, N. A., Redman, J. R., Eifel, P. J., Tucker, S. L., Cabanillas, F., & Kurzrock, R. (1996) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(96)90282-0 · Cited by 99
Self-citationGreer, J. P., Salhany, K. E., Cousar, J. B., Fields, J. P., King, L. E., Gräber, S. E., Flexner, J. M., Stein, R. S., & Collins, R. D. (1990) · Hematological Oncology · doi:10.1002/hon.2900080406 · Cited by 73
Cited by
Olsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., Knobler, R., Zackheim, H., Duvic, M., Estrach, T., Lamberg, S., et al. (2007) · Blood · doi:10.1182/blood-2007-03-055749 · Cited by 1,429
Self-citationThiers, B. H. (2008) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70989-4 · Cited by 974
Agar, N. S., Wedgeworth, E., Crichton, S., Mitchell, T. J., Cox, M., Ferreira, S., Robson, A., Calonje, E., Stefanato, C. M., Wain, E. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7665 · Cited by 853
Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., Yocum, R. C., & for Members of the Bexarotene Worldwide Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2456 · Cited by 706
Self-citationKim, Y. H., Liu, H. L., Mraz-Gernhard, S., Varghese, A., & Hoppe, R. T. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.7.857 · Cited by 653
Metadata
- Authors
- Diamandidou, E., Colome-Grimmer, M., Fayad, L., Duvic, M., & Kurzrock, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1998-08-15
- Volume
- 92
- Issue
- 4
- Pages
- 1150-1159
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W4249049999
- Cited by
- 334
- References
- 11
- FWCI
- 11.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis. https://app.cochat.ai/papers/10.1182/blood.v92.4.1150
- The paper
- Diamandidou, E., Colome-Grimmer, M., Fayad, L., Duvic, M., & Kurzrock, R. (1998). Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis. Blood. https://doi.org/10.1182/blood.v92.4.1150
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.